The therapeutic block of the CCL2/CCR2 axis has yielded promising results to slow the progression of several tumor types [39,40,41]; the therapy of melanoma-targeting CCR2 inhibited tumor growth in laboratory animals [42]. The gene discussed is CCL2; the disease is neoplasm.